Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Prostate Cancer

Free Subscription 05.10.2020 3 Anticancer Res 2 BJU Int 2 BMC Cancer 1 Br J Cancer 1 Br J Radiol 1 Cancer 1 Cancer Res 1 Eur Radiol 5 Eur Urol 1 Int J Cancer 3 Int J Radiat Oncol Biol Phys 1 J Clin Oncol 1 J Natl Cancer Inst 2 J Nucl Med 1 J Urol 1 Lancet Oncol 2 Oncogene 1 Oncol Rep 2 Oncology (Williston Park) 6 PLoS One 1 Prog Urol 2 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. MIYASHITA M, Tomogane M, Nakamura Y, Shimizu T, et al
   Sphere-derived Prostate Cancer Stem Cells Are Resistant to gammadelta T Cell Cytotoxicity.
   Anticancer Res. 2020;40:5481-5487.
   PubMed         Abstract available
   
   
2. YUNO T, Miyata Y, Matsuo T, Mukae Y, et al
   Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer.
   Anticancer Res. 2020;40:5567-5575.
   PubMed         Abstract available
   
   
3. KODITZ B, Fries JWU, GObel H, Paffenholz P, et al
   Mxi-2 Dependent Regulation of p53 in Prostate Cancer.
   Anticancer Res. 2020;40:5539-5544.
   PubMed         Abstract available
   
   

   
   BJU Int

4. DIAO W, Cao Y, Su D, Jia Z, et al
   (68) Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.
   BJU Int. 2020 Sep 26. doi: 10.1111/bju.15257.
   PubMed         Abstract available
   
   
5. STROMAN L, Cathcart P, Lamb A, Challacombe B, et al
   A cross-section of UK prostate cancer diagnostics during the COVID-19 era - a shifting paradigm?
   BJU Int. 2020 Sep 27. doi: 10.1111/bju.15259.
   PubMed         Abstract available
   
   

   
   BMC Cancer

6. KAWAHARA T, Kato M, Tabata K, Kojima I, et al
   A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
   BMC Cancer. 2020;20:919.
   PubMed         Abstract available
   
   
7. KAMDAR S, Fleshner NE, Bapat B
   A 38-gene model comprised of key TET2-associated genes shows additive utility to high-risk prostate cancer cases in the prognostication of biochemical recurrence.
   BMC Cancer. 2020;20:953.
   PubMed         Abstract available
   
   

   
   Br J Cancer

8. MOUT L, Moll JM, Chen M, de Morree ES, et al
   Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
   Br J Cancer. 2020 Sep 29. pii: 10.1038/s41416-020-01105.
   PubMed         Abstract available
   
   

   
   Br J Radiol

9. WADERA A, Alabousi M, Pozdnyakov A, Kashif Al-Ghita M, et al
   Impact of PI-RADS 3 lesions on the diagnostic accuracy of MRI for detecting prostate cancer and the prevalence of prostate cancer within each PI-RADS category: A systematic review and Meta-Analysis.
   Br J Radiol. 2020 Oct 1:20191050. doi: 10.1259/bjr.20191050.
   PubMed         Abstract available
   
   

   
   Cancer

10. LI CY, Chen LC, Lin HY, Lee MS, et al
    Impact of 23-valent pneumococcal polysaccharide vaccination on the frequency of pneumonia-related hospitalization and survival in elderly patients with prostate cancer: A seven-year nationwide matched cohort study.
    Cancer. 2020 Sep 30. doi: 10.1002/cncr.33203.
    PubMed         Abstract available
    
    

    
    Cancer Res

11. BEKETOVA E, Fang S, Owens JL, Liu S, et al
    Protein arginine methyltransferase 5 promotes pICln-dependent androgen receptor transcription in castration-resistant prostate cancer.
    Cancer Res. 2020 Sep 30. pii: 0008-5472.CAN-20-1228.
    PubMed         Abstract available
    
    

    
    Eur Radiol

12. GIGANTI F, Stabile A, Stavrinides V, Osinibi E, et al
    Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort.
    Eur Radiol. 2020 Sep 30. pii: 10.1007/s00330-020-07256.
    PubMed         Abstract available
    
    

    
    Eur Urol

13. ROYCE TJ, Wang AZ, Chen RC
    Quality-of-life Benefits and Harms from Prostate Radiotherapy in Patients with Low-burden Metastatic Prostate Cancer.
    Eur Urol. 2020 Sep 24. pii: S0302-2838(20)30721.
    PubMed        
    
    
14. BOEVE L, Hulshof MCCM, Verhagen PCMS, Twisk JWR, et al
    Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORR
    Eur Urol. 2020 Sep 22. pii: S0302-2838(20)30640.
    PubMed         Abstract available
    
    
15. CUMBERBATCH M, Condon B, Lawrentschuk N, Murphy DG, et al
    Re: Olaparib for Metastatic Castration-resistant Prostate Cancer.
    Eur Urol. 2020 Sep 23. pii: S0302-2838(20)30724.
    PubMed        
    
    
16. DARST BF
    Findings from a Genetic Sequencing Investigation of Men with Familial and Aggressive Prostate Cancer.
    Eur Urol. 2020 Sep 26. pii: S0302-2838(20)30693.
    PubMed        
    
    
17. ACHARD V, Dal Pra A, Zilli T
    Re: Carlo A. Bravi, Nicoal Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Eur Urol. In press. https://doi.o
    Eur Urol. 2020 Sep 29. pii: S0302-2838(20)30695.
    PubMed        
    
    

    
    Int J Cancer

18. WU J, Wei Y, Pan J, Jin S, et al
    Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33324.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

19. BERK L, Lopez Alfonso JC
    Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer In Regard to Vogelius et al.
    Int J Radiat Oncol Biol Phys. 2020;108:834.
    PubMed        
    
    
20. THOMPSON AB, Hamstra DA
    Rectal Spacer Usage with Proton Radiation Therapy for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2020;108:644-648.
    PubMed        
    
    
21. SANDERS JW, Venkatesan AM, Levitt CA, Bathala T, et al
    Fully balanced SSFP without an endorectal coil for post-implant QA of MRI-assisted radiosurgery (MARS) of prostate cancer: a prospective study.
    Int J Radiat Oncol Biol Phys. 2020 Sep 24. pii: S0360-3016(20)34342.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

22. CASTRO MENDEZ L, Martell K, Crook JM
    Brachytherapy and Androgen-Deprivation Therapy in Patients With Intermediate- and High-Risk Prostate Cancer: Not Necessarily an Either/Or Decision.
    J Clin Oncol. 2020 Sep 30:JCO2001566. doi: 10.1200/JCO.20.01566.
    PubMed        
    
    

    
    J Natl Cancer Inst

23. HURWITZ LM, Agalliu I, Albanes D, Barry KH, et al
    Recommended definitions of aggressive prostate cancer for etiologic epidemiologic research.
    J Natl Cancer Inst. 2020 Oct 3. pii: 5917632. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Nucl Med

24. BUCKNOR MD, Lichtensztajn DY, Lin TK, Borno HT, et al
    Disparities in PET imaging for prostate cancer at a tertiary academic medical center.
    J Nucl Med. 2020 Sep 25. pii: jnumed.120.251751. doi: 10.2967/jnumed.120.251751.
    PubMed         Abstract available
    
    
25. TORIIHARA A, Nobashi T, Baratto L, Duan H, et al
    Comparison of three interpretation criteria of (68)Ga-PSMA11 PET based on inter- and intra-reader agreement.
    J Nucl Med. 2019 Sep 27. pii: jnumed.119.232504. doi: 10.2967/jnumed.119.232504.
    PubMed         Abstract available
    
    

    
    J Urol

26. CHUANG R, Kinnaird A, Kwan L, Sisk A, et al
    Hemigland Cryoablation of Clinically Significant Prostate Cancer: Intermediate-Term Followup via Magnetic Resonance Imaging Guided Biopsy.
    J Urol. 2020 Sep 28:101097JU0000000000001133. doi: 10.1097/JU.0000000000001133.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

27. SARGOS P, Chabaud S, Latorzeff I, Magne N, et al
    Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
    Lancet Oncol. 2020;21:1341-1352.
    PubMed         Abstract available
    
    

    
    Oncogene

28. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2020 Sep 28. pii: 10.1038/s41388-020-01479.
    PubMed         Abstract available
    
    
29. QIAN K, Wang G, Ju L, Liu J, et al
    A novel germline EGFR variant p.R831H causes predisposition to familial CDK12-mutant prostate cancer with tandem duplicator phenotype.
    Oncogene. 2020 Sep 25. pii: 10.1038/s41388-020-01476.
    PubMed         Abstract available
    
    

    
    Oncol Rep

30. HE G, Li M, Fang L, Xu L, et al
    NMyc induces the tumor progression of prostate cancer by regulating FSCN1.
    Oncol Rep. 2020;44:2265-2274.
    PubMed         Abstract available
    
    

    
    Oncology (Williston Park)

31. MOUL JW
    Are COVID-19 Delays a Basis for Concern? Can We Use This for Future Good?
    Oncology (Williston Park). 2020;34:344-345.
    PubMed         Abstract available
    
    
32. WRIGHT KM
    Two Retrospective Analyses Show No Associated Adverse Outcomes With Delayed RP.
    Oncology (Williston Park). 2020;34:344-345.
    PubMed         Abstract available
    
    

    
    PLoS One

33. LI AH, Palmer KS, Taljaard M, Paterson JM, et al
    Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study.
    PLoS One. 2020;15:e0236480.
    PubMed         Abstract available
    
    
34. FIORICA PN, Schubert R, Morris JD, Abdul Sami M, et al
    Multi-ethnic transcriptome-wide association study of prostate cancer.
    PLoS One. 2020;15:e0236209.
    PubMed         Abstract available
    
    
35. YONG C, Moose DL, Bannick N, Gutierrez WR, et al
    Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
    PLoS One. 2020;15:e0232807.
    PubMed         Abstract available
    
    
36. GONCU B, Sevgi E, Kizilarslan Hancer C, Gokay G, et al
    Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0238303.
    PubMed         Abstract available
    
    
37. CARLSON AS, Acevedo RI, Lim DM, Gulati R, et al
    Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    PLoS One. 2020;15:e0239686.
    PubMed         Abstract available
    
    
38. SANDEMAN K, Eineluoto JT, Pohjonen J, Erickson A, et al
    Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    PLoS One. 2020;15:e0235779.
    PubMed         Abstract available
    
    

    
    Prog Urol

39. MJAESS G, Karam A, Aoun F, Albisinni S, et al
    COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
    Prog Urol. 2020;30:484-487.
    PubMed         Abstract available
    
    

    
    Prostate

40. VICIER C, Ravi P, Kwak L, Werner L, et al
    Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Prostate. 2020 Sep 28. doi: 10.1002/pros.24079.
    PubMed         Abstract available
    
    
41. KAUR H, Samarska I, Lu J, Faisal F, et al
    Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Prostate. 2020;80:1012-1023.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: